The distribution of drug monotherapy and combination therapy in patients with pulmonary arterial hypertension.

The distribution of drug monotherapy and combination therapy in patients with pulmonary arterial hypertension.</p

Cumulative survival curve of patients with pulmonary arterial hypertension.

(A) The 1-year, 2-year, and 3-year estimated survival rates shown are 84.9%, 62.2%, and 54.3%, respectively. (B). Primary outcome: cumulative survival curve of patients with pulmonary arterial hypertension according to etiology. IPAH, idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension.</p

Pulmonary arterial hypertension etiological breakdown of patients at enrolment.

Pulmonary arterial hypertension etiological breakdown of patients at enrolment.</p

Inclusion flow diagram of newly diagnosed pulmonary arterial hypertension patients enrolled in the study.

PAH, pulmonary arterial hypertension; ICD-10, International Classification of Diseases-Tenth Revision.</p

Distribution and trend of prescribed pulmonary arterial hypertension-specific drugs.

Distribution and trend of prescribed pulmonary arterial hypertension-specific drugs.</p

The baseline characteristics and comorbid conditions of all patients and their respective percentages according to the specific etiologies.

The baseline characteristics and comorbid conditions of all patients and their respective percentages according to the specific etiologies.</p

The trend of right catheter catheterization according to etiology in newly diagnosed patients per year.

IPAH, idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension.</p